Cara Therapeutics, Inc. - KALM-1 Pivotal Phase 3 Trial of KORSUVA™ Injection in Hemodialysis Patients with Pruritus Call Transcript
Good day, and welcome to the Cara Therapeutics KALM-1 Top Line Data Conference Call. (Operator Instructions) Please be advised that this call is being recorded at Cara's request. I will now like to turn the conference over to Cara team. Please proceed.
Good morning. This is Michael Schaffzin with Stern Investor Relations, and welcome to Cara Therapeutics KALM-1 Top Line Data Conference Call. The news release became available at 7:00 a.m. today and can be found at our -- on our website at www.caratherapeutics.com. You may also listen to a live webcast and replay of today's call in the Investors section of the website. A slide deck to accompany this call is also available for download on the Events & Presentations section at the Cara website.
Before we begin, let me remind you that statements made on today's call regarding matters that are not historical facts are forward-looking statements within the meaning of the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |